Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | KIF11 | P52732 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9216909 | 0.87 | FABP4 (0.53) | ADRA2CADRA1AADRA1BFABP4FABP5 | |
| SCHEMBL9208872 | 0.84 | POLB (0.55) | ALDH1A1SMN1; SMN2ADRA2CADRA1AADRA1B | |
| SCHEMBL20090414 | 0.83 | EPHX2 (0.49) | ALDH1A1SMN1; SMN2ADRA2CADRA1AADRA1B | |
| SCHEMBL17170051 | 0.83 | ADRA2C (0.52) | ALDH1A1SMN1; SMN2ADRA2CADRA1AADRA1B | |
| SCHEMBL1120903 | 0.81 | ADRA2C (0.51) | ALDH1A1SMN1; SMN2ADRA2CADRA1AADRA1B | |
| SCHEMBL7355242 | 0.81 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2HPGDPOLBKDM4E | |
| SCHEMBL857789 | 0.80 | BRAF (0.59) | HPGDAURKADAPK3JAK2KDR | |
| Hydrochloric Acid SCHEMBL9209804 | 0.80 | ADRA2C (0.57) | ALDH1A1SMN1; SMN2ADRA2CADRA1AADRA1B | |
| SCHEMBL1120898 | 0.80 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2HPGDKIF11EPHX2 | |
| SCHEMBL7845841 | 0.78 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2HPGDPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| CN-1043526-C | Sulfoneanilide derivative and application of same in medicine | NIPPON SHINYAKU CO LTD (JP) | 1999-06-02 | — | — | CN | disclosed |
| EP-0538469-B1 | SULFONANILIDE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 1995-09-27 | — | — | EP | disclosed |
| US-5360822-A | FOR TREATING URINARY INCONTINENCE IN ANIMALS AND HUMANS | NIPPON SHINYAKU CO. LTD. (JP) | 1994-11-01 | — | — | US | disclosed |
| EP-0538469-A1 | SULFONANILIDE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | ALDH1A1 4348/4885SMN1; SMN2 1839/4885ADRA2C 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.